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Polycomb group proteins have long been linked to the occurrence of different forms of cancer. Polycomb proteins form at least
twodistinctcomplexes,thePolycomb-repressivecomplexes1and2(PRC1andPRC2).SomeofthePRC complex subunitshave
been found to be overexpressed in a variety of different tumors. Epigenetic perturbations are likely to be the cause for
transcriptional misregulation of tumor suppressor genes and of certain cell fates. It is especially critical for stem cells that their
potential to self-renewal and to differentiate is tightly controlled and properly orchestrated. Misregulation of Polycomb protein
levels often leads to either a block or unscheduled activation of developmental pathways, thereby enhancing the proliferation
capability of a cell. The consequences of this misregulation have been linked to the establishment of cancer stem cells, which
can produce tumors through a combination of increased self-renewal and the lack of complete cellular differentiation. Cancer
stem cells are believed to persist within tumors and to elicit relapse and metastasis. In this review, we recapitulate the roles of
Polycomb proteins in stem cell biology, and the impact their misregulation can have on cancer.
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Mechanisms of Gene Regulation by Polycomb and
Trithorax Complexes
Polycomb proteins were initially identiﬁed in Drosophila
melanogaster as genes important for developmental path-
ways. Mutations in Polycomb proteins cause developmental
defects due to misregulation of speciﬁc transcriptional
cascades that involve key transcription factors, such as the
Homeobox protein; this leads to typical homeotic pheno-
types.
1,2 Recent researchhasexpanded ourunderstandingof
the mechanistic basis of Polycomb functions, explaining, for
example, how such homeotic phenotypes occur.
3,4 However,
many aspects of the molecular mechanism are still elusive. In
ﬂies, the Polycomb complexes that are recruited to chromatin
at the Polycomb responsive elements work to silence genes,
whereas proteins of the Trithorax family counteract this to
activate the same genes.
2 It is still unclear how Polycomb
proteins are recruited to chromatin in mammalian cells.
However, the epigenetic mechanisms of gene silencing by
Polycomb-repressive complexes (PRCs) is conserved in
eukaryotes (Figure 1).
4,5 The two Polycomb complexes,
PRC1 and PRC2, have been characterized in depth. It has
beendemonstrated thatthetwo complexes cansilence genes
either synergistically or independently of each other.
6,7
However, existing evidence indicates that PRC2 is involved
in recruiting the PRC1 complex to promoters of their common
target genes.
8,9 In mammals, PRC2 consists of at least four
subunits, one of which is EZH2, a histone methyltransferase
(HMT) that catalyzes the trimethylation of the histone H3 at
lysine 27 (H3K27me3) via its SET domain.
10 The trimethyl
modiﬁcation at H3K27 is a hallmark for gene repression and is
usually found in the promoter regions of developmental
genes.
11 It has been demonstrated that this modiﬁcation is
the docking site for proteins harboring a chromobox (CBX)
domain. The CBX protein family can function as subunits of
the PRC1 complex, and it is believed that the CBX proteins
help to recruit the PRC1 complex to chromatin through their
interactions with H3K27me3 modiﬁcations set by PR2.
12
PRC1 catalyzes the subsequent monoubiquitylation of lysine
119 at histone H2A (H2AK119ub) by the enzymatic action of
the two ring domain-containing proteins, RING1B and
Bmi-1.
13,14 Although this hierarchical model of Polycomb
recruitment to genes seems to apply in many cases, it was
recently challenged by the ﬁnding that PRC1 and PRC2 are
not always located at the same genomic loci.
7
The monoubiquitin mark represents one of the most
abundant epigenetic modiﬁcations and decorates about
10% of endogenous H2A proteins. The original report that
ubiquitinated H2A protein helps to maintain gene silencing
has been controversial, as this mark was also found in
transcribed chromatin regions of D. melanogaster.
15 A recent
study has now demonstrated that chromatin condensation is
notdependentonthemonoubiquitinmarkperse,butratheron
Received 12.5.11; accepted 09.6.11; Edited by P Salomoni
1Department of Differentiation and Cancer, Centre de Regulacio ´ Geno `mica (CRG), Universitat Pompeu Fabra, Barcelona, Spain;
2Institute of Molecular Biology (IMB),
Mainz, Germany and
3Institucio ´ Catalana de Recerca i Estudis Avanc ¸ats (ICREA), Barcelona, Spain
*Corresponding author: L Di Croce, Department of Differentiation and Cancer, Centre de Regulacio ´ Geno `mica (CRG), 08003 Barcelona, Spain. Tel: þ34 93 316 0132;
Fax: þ34 93 224 0899; E-mail: luciano.dicroce@crg.es
Keywords: Polycomb group proteins; embryonic stem cells; cancer stem cells
Abbreviations: CBX, chromobox; CTD, C-terminal domain; DNMT, DNA methyltransferase; ES cells, embryonic stem cells; HMT, histone methyltransferase; NSCs,
neural stem cells; PCL, Polycomb-like; PLZF, promyelocytic leukemia zinc ﬁnger; PRC, Polycomb repressive complex; Pol II, polymerase II; TrxG, trithorax group
Citation: Cell Death and Disease (2011) 2, e204; doi:10.1038/cddis.2011.84
& 2011 Macmillan Publishers Limited All rights reserved 2041-4889/11
www.nature.com/cddisPRC1 itself,
16 supporting previous in vitro results that
revealed that PRC1 helps to compact chromatin arrays.
17
Indeed, we have recently found that the ubiquitin residue has
a functional role as a platform for transcriptional activation.
18
PRC1 also seems to block the transcriptional elongation of
polymerase II (Pol II) at so-called bivalent genes, which are
decorated with both repressive and activating trimethyl marks
(H3K27me3 and H3K4me3, respectively; Figure 1).
19 At
these bivalent genes, RNA Pol II (phosphorylated in its
C-terminal domain (CTD) at serine 5) is paused within the
gene body, poised for activation upon differentiation stimuli.
PolIIpausingmostlikelyisduetotheoccupancyofPRC1and
the incorporation of the monoubiquitin mark at these loci;
20
however, the exact molecular mechanism of this still needs to
be elucidated.
In addition to these rather direct actions of the Polycomb
complexes, another layer of epigenetic silencing is brought
about by their interaction with the DNA methylation system.
Methylation of DNA at cytidine residues within CPG islands is
one of the most well-characterized mechanisms of gene
silencing.
21 The PRC2 subunit EZH2 was demonstrated to
interactwith DNAmethyltransferases (DNMTs). Furthermore,
PRC2 and DNMTs have been shown to be recruited to
chromatin by the oncogenic fusion protein PML-RARa, which
originates from a genetic translocation that causes acute
leukemia.
22,23 Likewise, Bmi-1 (within the PRC1 complex) is
recruited by the transcription factor promyelocytic leukemia
zinc ﬁnger (PLZF), a member of the BTB/POZ-ZF family of
transcription factors.
24 In leukemia, the oncogenic fusion-
protein PLZF-RARa causes aberrant recruitment of PRC1.
25
Thus, Polycomb complexes are often recruited by transcrip-
tionfactorsthatregulatecellfateandtherebylockgenesintoa
silenced state, either directly or indirectly by further recruiting
DNMTs.
Polycomb targets include tumor suppressor genes, which
function to keep uncontrolled proliferation at bay. Polycomb-
mediated silencing of those genes prevents the cell from
undergoing senescence, which might ultimately lead to the
occurrence of cancer. Indeed, Polycomb complexes silence
the CDKN2A and CDKN2B loci, which encode the tumor
suppressors p14 (ARF), p15 (INK4B) and p16 (INK4A).
26–28
Overexpression of Polycomb proteins leads to transcriptional
repression of those loci, thereby inhibiting senescence and
enhancing proliferation. The PRC2 subunit EZH2 has also
been reported to have a pivotal role in apoptosis. EZH2
repressestheexpressionoftheDAB2-interacting protein,and
thus, prohibits apoptosis meditated by the tumor necrosis
factor.
29 More recently, it was demonstrated that EZH2
directly regulates the apoptotic process in cancer cells by
repressing the E2F1 target Bim.
30 Given the involvement of
Polycomb proteins in senescence and apoptosis, it is under-
standablethattheirmisregulationisstronglyrelatedtocancer.
Proteins that counteract Polycomb function are also often
implicated in cancer. A broad body of work has demonstrated
thatthetrithoraxgroup(TrxG)proteinscounteractthefunction
of Polycomb proteins and thereby activate genes.
2,31 TrxG
proteins form multi-protein complexes that, like the Polycomb
proteins, deposit histone marks that are linked to transcrip-
tional activation. TrxG complexes usually comprise of HMTs
that contain SET-domains, which methylate lysine 4 of histone 3
(H3K4me3), an activating chromatin mark.
2 In sum, mis-
regulation of members of the Polycomb and TrxG families,
and of proteins that either interact with them or have an effect
on their occupancy at chromatin, usually leads to a cancer
phenotype.
Polycomb Group Complexes and their Role in
Embryonic Stem (ES) Cells
In the last few years, ES cells have emerged as an excellent
model system for elucidating the mechanisms governing cell
fate transition during mammalian development. ES cells are
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Figure 1 Epigenetic modiﬁcations at bivalent genes. Bivalent genes are earmarked by activating and repressive epigenetic marks. MLL complexes decorate chromatin
with an activating H3K4me3mark. The consecutive action of PRC2 and PRC1 complexes leadsto dispositionof repressive marks at chromatin. PRC2 carries out the speciﬁc
methylation (H3K27me3), which is thought to recruit PRC1 via proteins of the CBX family. PRC1 complexes subsequently transfer a monoubiquitin residue to histone H2A
(H2AK119). Both, PRC1 and monoubiquitinated histone H2A (H2Aub) lock chromatin in a silenced state and force Pol II to remain in a paused state
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Cell Death and Diseasederived from the inner cell mass of the pre-implantation
embryoatthestageofblastocyst(3.5dayspostcoitum(dpc)).
A hallmark of ES cells is their pluripotency, which bestows
them with the ability to give rise to all cell types of an embryo
except the trophoectoderm.
32,33 When reintroduced into host
blastocysts, ES cells contribute to generate all cell types,
including germ cells, and give rise to chimeras. In ES cells,
pluripotency is maintained by the prevention of differentiation
and the promotion of proliferation. Thus, ES cells can self-
renew continuously in vitro if they are cultured under the
proper conditions. Differentiation of ES cells in vitro recapi-
tulates the same hierarchical steps of embryo development
that occurs in vivo. During development, lineage-speciﬁc
transcription factors are regulated by epigenetic events that
impose either a permissive or a repressive environment over
cell fate.
PRC1andPRC2arekeyfactorsintheepigeneticregulation
of developmental loci, impeding the transcription of these
through repressive marks.
11,34 Still, in most of the PRC target
loci in ES cells, the activating H3K4me3 mark is also present.
As mentioned above, according to the current model, PRC1
and PRC2 colocalize to these so-called bivalent domains,
regulating the expression of many important developmental
genes.
35,36Interestingly,bivalentdomainshaverecentlybeen
identiﬁed that are exclusively bound by PRC2.7 These PRC2-
containing bivalent domains are only weakly conserved and,
in contrast to domains decorated by both PRC1 and PRC2,
correspond to genes encoding for membrane proteins or
unknown functions. The peculiar chromatin signature of
bivalent domains renders the respective developmental
genes poised for activation, so that induction of transcription
upondifferentiationstimuli canoccurextremelyrapidly.
37This
ability to respond rapidly is supported by the RNA Pol II that is
phosphorylated at serine 5 of its CTD, which is enriched at
manyPRC1/PRC2 targets in ES cells.
37 Bivalent domains are
present in embryos beginning at the eighth cell stage and last
untiltheblastocyststage,atwhichpointthecellsseparateinto
two different populations, the inner cells, from which the ES
cellsarise,andtheextra-embryoniclayer.
38Asubsetofgenes
in extra-embryonic cells still retain the bivalent domains, but
these loci no longer have PRC1 and RNA Pol II recruited to
them, although PRC2 is still present. A key role in the extra-
embryonic cells is now had by Suv39h1, which directly targets
the bivalent genes and catalyzes the speciﬁc trimethylation of
lysine 9 in histone H3 (H3K9me3). Thus, PRC1 and Suv39h1
are mutually exclusive in specifying the fate of the bivalent
domains during blastocyst formation.
ThebivalentdomainstendtodisappearuponfurtherEScell
differentiation. However, depending on the expression of the
gene in the particular cell context, the activating mark
H3K4me3 or the repressive H3K27me3 can be maintained
in the loci.
39,40 For instance, most of the bivalent domains
present in ES cells resolve upon differentiation to neural stem
cells (NSCs). The H3K4me3 mark remains only at the
promoters of genes that are transcriptionally upregulated
duringneurogenesis,whereasmarkergenesofotherlineages
display increased levels of H3K27me3.
41 On the other hand,
Mohnetal.
42suggestthatonlyasubsetofPolycombtargetsis
determined in ES cells and that, upon cell fate commitment
and establishment of progenitor cells, certain genes acquire
bivalent domains. According to this study, the overall number
of bivalent domains does not seem to change between ES
cells and neural progenitors, as loss during differentiation is
largely compensated by newly formed bivalent domains in
differentiated cells at different states. This observation
supports the fact that bivalent domains are not a unique
feature of ES cells, but are also found in others stem cells,
suchasmesenchymalstemcellsandhematopoieticstemand
progenitor cells.
39,43 Taken together, these data underline the
important role of the bivalent domains, and therefore of PRC1
and PRC2, in maintaining stem cell characteristics. Along
these lines, Vastenhouw et al.
44 provided evidence that
bivalent domains are present at a subset of genes in early
embryosofzebraﬁsh,demonstratingthatthefunctionofthese
domains is evolutionary conserved.
Role of PRC2 in Embryonic Stem (ES) Cells
PRC2 is strongly involved in the early steps of embryo-
genesis, and both EZH2 and EED knockout mice display
embryonic lethality soon after implantation (Table 1).
45–47
However, PRC2 is not necessary for maintaining ES cell self-
renewal, as each of the PRC2 components can be deleted
without compromising the expression levels of pluripotent
markers, such as Oct4 and Nanog.
48,49 As mentioned above,
PRC2 is involved in the expression of developmental genes,
and ES cells lacking Suz12, EED or EZH2 show aberrant
de-repression of lineage-speciﬁc genes and are unable to
properly differentiate. This is partially also due the lack of
repression of pluripotent genes during differentiation steps.
Accordingly, EED-knockout ES cells are able to give rise to
chimeras, conﬁrming that they are pluripotent in vivo.
However, despite the robust occurrence of EED-depleted
cells in chimeric embryos at 9.5 dpc, they are scarce at 12.5
dpc due to lethality of differentiated cells, as shown by
Chamberlain et al.
49
In addition to the core subunits of PRC2, other PRC2-
associated proteins affect the enzymatic activity of the core
complex, at least in ES cells. Jarid2 is a member of the
Jumonji proteins, which constitute a family of histone
demethylases, although Jarid2 lacks the enzymatic activity.
ItwasrecentlyreportedthatJarid2associateswithPRC2,and
that it is required for proper embryo development.
50 In
contrast to EED knockout ES cells, Jarid2 knockout ES cells
do not result in the de-repression of most of the PRC2 target
genes, suggesting that Jarid2 is not essential in PRC2-
mediated gene repressionin ES cells. Yet Jarid2 knockout ES
cells are unable to properly differentiate, probably because
the recruitment of PRC1 and RNA polymerase to bivalent
domains is strongly reduced.
51
In D. melanogaster, the family of Polycomb-like (PCL)
proteins forms a subset of PRC2 complexes. Of the three
mammalian orthologs (PHF1, PHF19 and PCL2), PCL2 has
been investigated in the context of stem cells. PCL2 knock-
down in ES cells displays higher levels of Oct4 and Nanog,
indicating that it is involved in the control of self-renewal.
52–54
Theincreaseofthesepluripotentmarkersseemstobeadirect
consequence of PCL2-dependent transcriptional silencing of
Tbx3 and Klf4, which are key factors involved in the
maintenance of ES cells in an undifferentiated state, and in
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Cell Death and Diseasereprogramming somatic cells into induced pluripotent stem
cells.
55,56 In addition, PCL2 knockdown cells are not able to
properlydifferentiate,astheyalsomaintainhighlevelsofOct4
and Nanog during neuroectodermal differentiation and show
abnormalities in embryoid body formation.
Role of PRC1 in Stem Cell Self-renewal and
Differentiation
Similar to the knockout of PRC2 proteins, knockout of the E3
ligase Ring1B causes gastrulation arrest and results in
embryonic lethality,
57 demonstrating that both PRC com-
plexes are essential for development (Table 1). ES cells
devoid of Ring1B are capable of maintaining the proper
expression of some pluripotency markers, such as Oct4 and
Nanog.
58 Analogous to EED knockout ES cells, Ring1B
knockout ES cells display a derepression of the PRC1-target
genes and are impaired in proper differentiation.
59 Further-
more, Ring1B knockout mice display the most severe
phenotype among the members of PRC1.
Mice deﬁcient for Mel18 or Bmi-1 exhibit similar posterior
transformations of the axial skeleton and display severe
immune deﬁciency.
60–62 This result supports the hypothesis
that Mel18 and Bmi1 can act redundantly.
63 However, this
interpretation is in part challenged by the unique phenotypes
observed in either Mel18 or Bmi-1 knockout mice, which is
suggestive of different functions for Mel18 and Bmi-1. For
instance, abnormalities in the cerebellum were observed only
in Bmi-1 knockout mice, whereas intestinal obstruction due to
hypertrophy of the smooth muscle layer was observed only in
Mel-18 mutants.
The integrity of the PRC1 complex appears to be critical for
stem cell maintenance. For instance, embryonic neural stem
cells require Ring1B for maintaining proper undifferentiated
features, as reported by Roma ´n-Trufero et al.
64 Indeed, the
Ring1B knockout NSCs had an upregulation of several
differentiation markers and of the cell proliferation inhibitor
p21. Likewise, Bmi1 was demonstrated to control p21
expression in embryonic NSCs.
65 Moreover, Bmi1 is also
important for self-renewal of post-natal NSCs, mediating the
suppression of the Ink4/Arf cell cycle inhibitor proteins, p16
and p19.
66 NSCs that overexpress Bmi1 show an increase in
their proliferation and self-renewal potential without eliciting a
neoplastic transformation.
67 Bmi1 is important not only for
NSCs, but also for a vast number of different stem cell
lineages. Bmi1 is essential for multipotency of hematopoietic
stemcellsand multipotent progenitors,asit controls the B-cell
lineage developmental regulators of Ebf1 and Pax5. Bmi1
depletion leads to an accelerated lymphoid speciﬁcation and
to a marked reduction in the stem cell compartment.
68
Additionally, in prostate stem cells, Bmi1 is involved in the
control of the self-renewal of p63-positive stem cells.
69
Redundancy of the PRC Complex in ES Cells
The functional relevance of the PRC complex in ES cells has
been highlighted by the fact that neither EED nor Ring1B
knockout ES cells able to reprogram human B lymphocytes
into pluripotent cells, suggesting that PRC complexes are
necessarynotonlytomaintain,butalsotoestablishproperES
cell pluripotency.
70 However, the mechanismof actionofPRC
complexes has not been fully elucidated. According to the
proposed model of PRC action at chromatin, both complexes
– and thus both epigenetic modiﬁcations – should decorate
the nucleosomes of developmental target genes. This model
has been challenged by Leebet al.,
6 who suggest that the two
complexes are, at least in part, independent and act
redundantly. In Ring1B/EED double-knockout ES cells, the
number of de-repressed genes, which are direct PRC targets,
increased about two times, compared with the single EED or
Ring1Bknockout.Halfofthesegeneswerede-repressedonly
after the loss of both PRC1 and PRC2, and remained
repressed in each single knockout, suggesting that PRC1
and PRC2 are redundant for repression of these genes.
Table 1 Molecular and biological functions of PRC1 and PRC2 components
Human Polycomb protein Function Stem cell/cancer phenotype
PRC1
RING1a, RING1b Monoubiquitylation of histone H2A RING1B KO ESCs show aberrant expression of differentiation
markers and are unable to properly differentiate
CBX2, CBX4, CBX7, CBX8 Binding of tri-methylated Lysines
(H3K27me3)
Unknown
BMI1, MEL18, MBLR, NSPC1 Unknown Bmi1 depletion impairs neural, hematopoietic and prostate stem
cell self-renewal
Overexpressed in many types of cancer
PHC1, PHC2, PHC3 Unknown Unknown
Human Polycomb protein Function Stem cell Phenotype
PRC2
EZH2, EZH1 Methylation of histone H3 (H3K27me3) EZH2 KO ESCs show aberrant expression of differentiation
markers and are unable to properly differentiate
Overexpressed in many types of cancer
SUZ12 Unknown SUZ12 KO ESCs are unable to properly differentiate
EED Binding of tri-methylated Lysines
(H3K27me3
EED KO ESCs are unable to properly differentiate
RBBP4, RBBP7 Binding of Histone proteins
PCL1, PCL2, PCL3, JARID2 Unknown PCL2 KO ESCs displays higher levels of pluripotency markers
and are unable to properly differentiate
Jarid2 KO ESCs are unable to properly differentiate
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Cell Death and DiseaseThis observation is buttressed by the ‘rescue’ of gene
repression by inducing EED expression in the double knockout
ES cells. Additionally, PRC1 is recruited to these redundantly
silenced genes, albeit at low (but still detectable) levels,
independently of PRC2, providing a further challenge to the
current model of hierarchical PRC1 recruitment. This mechan-
ism is gene speciﬁc, as some other PRC targets do not need
the loss of both PRC1 and PRC2 complex, but are already de-
repressed in the absence of either PRC1 or PRC2 alone.
Finally, the ability to differentiate is compromised in Ring1B
and EED: the single knockout ES cells form teratomas much
smaller than the control cells, but the capability of forming
teratomas is completely abolished by the double knockout,
supporting the functional redundancy of the two complexes.
6
Polycomb Proteins and Cancer
Studying how Polycomb protein misregulation leads to a
variety of different tumors has revealed in the last years the
oncogenic potential of Bmi-1 (in PRC1) and EZH2 (in
PRC2).
71 Both proteins are often overexpressed in cancers.
In bladder tumors, EZH2 displays increased expression
levels,
72 which directly correlate with the invasive potential
of the carcinomas. Similar ﬁndings were obtained for prostate
and breast cancers,
73,74 and deregulation of EZH2 was also
directly linked to the emergence of colorectal cancer and oral
squamous carcinomas.
75,76 Increased Bmi-1 protein levels
are found in very different forms of cancer, which suggest that
Bmi-1 has an important role in PRC1 action in addition to
supporting the Ring1B-catalyzed enzymatic action at chro-
matin. Bmi-1 protein levels are elevated in squamous cell
carcinomas,
77 neuroblastomas
58 and bladder tumors,
78 and
several studies describe its deregulation in leukemia.
79
Furthermore, there is evidence for an increased co-expres-
sion of proteins from both Polycomb complexes in several
typesoftumors.
80,81AplethoraofpublicationslinksPolycomb
proteins to cancer and, more recently, to the occurrence of
cancer stem cells. Additionally, PRCcomplexes are important
during embryogenesis, as has been demonstrated by the
early embryonic lethality of Ring1b and EZH2 knockout
mouse models.
There is increasing evidence that PRC complexes have a
role in tumor progression and development by blocking
differentiation and promoting stem cell self-renewal. A recent
study demonstrated that enhanced EZH2 levels led to growth
of Ewing tumors and a consequential inhibition of endothelial
and neuroectodermal differentiation.
82 Similarly, Bmi-1
seems to have a pivotal role in lung cancerogenesis. K-ras-
initiated lung tumorigenesis was drastically compromised in
Bmi-1 null mice, as loss of Bmi-1 caused a reduced self-
renewal capacity and limited the expansion of cancer stem
cells.
83 In glioblastomas, both Bmi-1 and EZH2 have divisive
roles: knockdown of EZH2 protein levels diminished the self-
renewal ability and the tumor-initiating capacity of cancer
stem cells,
84 whereas a microRNA-mediated downregulation
of Bmi-1 levels in glioblastomas inhibited the proliferation and
reduced self-renewal of the glioma stem cells.
85 In contrast to
these ﬁndings, knockdowns of EZH2 and Bmi-1 did not inhibit
osteosarcoma growth.
86
Regulation by the PRC complexes of pathways implicated
intheemergenceofcancerstemcells,suchastheHedgehog,
Wnt, and Notch pathways,
87,88 has important implications.
The Wnt protein was demonstrated to be a major factor in
colorectal cancers,
88 whereas Hedgehog was recently
implicated in maintaining cancer stem cells in leukemia.
89
Stem cells ﬁne-tune their expression proﬁles, likely through
Embryonic Stem cell
Self renewal
Terminally differentiated
Cells
PRC1/PRC2 integrity PRC1/PRC2
independent
Misregulation of Polycomb proteins:
lack of PRC1/PRC2 integrity
Adult stem cells
PRC1/PRC2
dependent
Self renewal
Cancer stem cell
Heterogenous
Tumor
Figure 2 Role of Polycomb proteins in the emergence of cancer stem cells. ES cells undergo asymmetric cell divisions that give rise to daughter cells (self-renewal) and
progenitor cells that ultimately differentiate into a distinct cell type. Integrity of Polycomb complexes is required for proper ES and adult stem cell differentiation. In addition,
PRC1 and PRC2 are required for the self-renewal of adult, but not embryonic, stem cells. Misregulation of the levels of the Polycomb group proteins can lead to the formation
of cancer stem cells, which maintain the ability to self-renew and undergo uncontrolled differentiation, leading to the generation of heterogenous tumors
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Cell Death and Diseasebivalent domains, and a lack of Polycomb components leads
to the aberrant upregulation of these mostly developmental
loci. Therefore, to guarantee stem cell renewal and pluripo-
tency, PRC proteins are essential. Cancer stem cells are
believed to be a subpopulation of cells with self-renewal
abilities, which reiterate the processes common to normal
stem cell self-renewal. In fact, some tumors contain embryo-
nic-like cells that likely originate from stem cells; this would
explain the occurrence of heterogeneous tumors (Figure 2).
Carcinomas that arise from stem cells, and accordingly show
gene expression proﬁles similar to stem cells, appear to be
quite aggressive and are prone to survive the cancer
treatment.
It has thus become increasingly clear that epigenetic
regulation has a critical role in determining stem cells fates.
Elucidating the mechanisms by which the PcG and TrxG
proteins act and interact to ﬁne-tune the regulation of cell fate-
speciﬁc genes is highly important for understanding this. As
these regulatory pathways are often impeded on in cancer
stem cells, this knowledge could offer us the possibility to
directly target misregulated pathways with speciﬁc drugs.
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